Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orvepitant in chronic cough in idiopathic pulmonary fibrosis
NCT05185089Phase 2Completed
- Sponsor
- NeRRe Therapeutics
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of orvepitant in chronic cough, sponsored by NeRRe Therapeutics. Started Aug 2022; status: completed.
02
Drugs
orvepitant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT05185089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185089.